Src Kinase Family Members Expression in Human Breast Tissue and Their Association to Clinical Outcome of Breast Cancer Patients.

2009 ◽  
Author(s):  
B. Elsberger ◽  
S. Zino ◽  
F. Jordan ◽  
R. Fullerton ◽  
T. Mitchell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Breast Tissue ◽  
Family Members ◽  
Src Kinase ◽  
Breast Cancer Patients ◽  
Human Breast ◽  
Human Breast Tissue ◽  
Kinase Family

1023 Are expression levels of Src kinase family members in human breast tissue related to clinical outcome of breast cancer patients?

2009 ◽  
Vol 7 (2) ◽  
pp. 93-94
Author(s):  
B. Elsberger ◽  
S. Zino ◽  
R. Fullerton ◽  
T.J. Mitchell ◽  
P. Shiels ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Breast Tissue ◽  
Family Members ◽  
Src Kinase ◽  
Breast Cancer Patients ◽  
Human Breast ◽  
Human Breast Tissue ◽  
Expression Levels

Differential Gene Expression of BRCA1, ERBB2 and TP53 Biomarkers between Human Breast Tissue and Peripheral Blood Samples of Breast Cancer Patients

2016 ◽  
Vol 16 (4) ◽  
pp. 519-525 ◽  
Author(s):  
Abdulrazzaq Neamah Zghair ◽  
Deepak Kumar Sinha ◽  
Arkan Kassim ◽  
Mohmmad Alfaham ◽  
Anil K. Sharma
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Breast Tissue ◽  
Breast Cancer Patients ◽  
Human Breast ◽  
Human Breast Tissue ◽  
Blood Samples ◽  
Differential Gene

scholarly journals Breast cancer patients’ clinical outcome measures are associated with Src kinase family member expression

2010 ◽  
Vol 103 (6) ◽  
pp. 899-909 ◽  
Author(s):  
B Elsberger ◽  
R Fullerton ◽  
S Zino ◽  
F Jordan ◽  
T J Mitchell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcome ◽  
Family Member ◽  
Cancer Patients ◽  
Outcome Measures ◽  
Src Kinase ◽  
Breast Cancer Patients ◽  
Kinase Family

scholarly journals Tumour Src kinase family member expression correlates with peritumoral inflammatory cell infiltrate in a cohort of early breast cancer patients

2013 ◽  
Vol 11 (8) ◽  
pp. 600
Author(s):  
Brian Stewart ◽  
Jenny Ferguson ◽  
Zahra Mohammed ◽  
Donald McMillan ◽  
Paul Horgan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family Member ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Inflammatory Cell ◽  
Src Kinase ◽  
Inflammatory Cell Infiltrate ◽  
Breast Cancer Patients ◽  
Cell Infiltrate ◽  
Kinase Family

High expression of Src kinase family members (SKFMs) in breast cancer specimens and their association to patients' clinical outcome

2009 ◽  
Vol 35 (11) ◽  
pp. 1237
Author(s):  
Beatrix Elsberger ◽  
R. Fullerton ◽  
B. Tan ◽  
T. Mitchell ◽  
J. Edwards
Keyword(s):  
Breast Cancer ◽  
Clinical Outcome ◽  
Family Members ◽  
Src Kinase ◽  
High Expression ◽  
Kinase Family

scholarly journals Expression of SRC Kinase Family Members in Tamoxifen Treated ER Positive Breast Cancer and Association with Clinical Outcome

2013 ◽  
Vol 24 ◽  
pp. iii29
Author(s):  
B. Elsberger ◽  
D. Paravasthu ◽  
S. Tovey ◽  
J. Edwards
Keyword(s):  
Breast Cancer ◽  
Clinical Outcome ◽  
Family Members ◽  
Src Kinase ◽  
Kinase Family ◽  
Er Positive ◽  
Positive Breast Cancer

scholarly journals Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 771
Author(s):  
Tessa A. M. Mulder ◽  
Mirjam de With ◽  
Marzia del Re ◽  
Romano Danesi ◽  
Ron H. J. Mathijssen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Plasma Concentrations ◽  
Tamoxifen Treatment ◽  
Current Status ◽  
Endocrine Treatment ◽  
Breast Cancer Patients ◽  
Er Positive ◽  
Positive Breast Cancer

Tamoxifen is a major option for adjuvant endocrine treatment in estrogen receptor (ER) positive breast cancer patients. The conversion of the prodrug tamoxifen into the most active metabolite endoxifen is mainly catalyzed by the enzyme cytochrome P450 2D6 (CYP2D6). Genetic variation in the CYP2D6 gene leads to altered enzyme activity, which influences endoxifen formation and thereby potentially therapy outcome. The association between genetically compromised CYP2D6 activity and low endoxifen plasma concentrations is generally accepted, and it was shown that tamoxifen dose increments in compromised patients resulted in higher endoxifen concentrations. However, the correlation between CYP2D6 genotype and clinical outcome is still under debate. This has led to genotype-based tamoxifen dosing recommendations by the Clinical Pharmacogenetic Implementation Consortium (CPIC) in 2018, whereas in 2019, the European Society of Medical Oncology (ESMO) discouraged the use of CYP2D6 genotyping in clinical practice for tamoxifen therapy. This paper describes the latest developments on CYP2D6 genotyping in relation to endoxifen plasma concentrations and tamoxifen-related clinical outcome. Therefore, we focused on Pharmacogenetic publications from 2018 (CPIC publication) to 2021 in order to shed a light on the current status of this debate.

scholarly journals The Expression Pattern of Epidermal Differentiation Marker Keratin 10 in the Normal Human Breast and Breast Cancer Cells

2020 ◽  
Vol 68 (8) ◽  
pp. 561-570
Author(s):  
Jiyoung Kim ◽  
René Villadsen
Keyword(s):  
Breast Cancer ◽  
Expression Pattern ◽  
Breast Tissue ◽  
Normal Breast ◽  
Epidermal Differentiation ◽  
Breast Cancer Patients ◽  
Human Breast ◽  
Normal Human Breast ◽  
Differentiation Marker ◽  
Breast Gland

Cells of the human breast gland express an array of keratins, of which some are used for characterizing both normal and neoplastic breast tissue. However, the expression pattern of certain keratins has yet to be detailed. Here, the expression of a differentiation marker of epidermal epithelium, keratin 10 (K10), was investigated in the human breast gland. While in normal breast tissue generally less than 1% of luminal epithelial cells expressed K10, in women >30 years of age glandular structures with K10-positive (K10pos) cells were found at higher frequency than in younger women. K10pos cells belong to a mature luminal compartment as they were negative for cKIT, positive for Ks20.8, and mostly non-cycling. In breast cancer, around 16% of primary breast carcinomas tested were positive for K10 by immunohistochemistry. Interestingly, K10pos tumor cells generally exhibit features of differentiation similar to their normal counterparts. Although this suggests that K10 is a marker of tumor differentiation, data based on gene expression analysis imply that high levels of K10 dictate a worse outcome for breast cancer patients. These findings can form the basis of future studies that should unravel which role K10 may play as a marker of breast cancer:

Sign in / Sign up

Export Citation Format

Share Document